TACTIC-E:COVID-19 入院前ICU患者的多臂治疗研究——实验药物与机制
TACTIC-E是一项随机、平行臂、开放标签、适应性平台2/3期试验,纳入晚期1期/2期COVID-19相关疾病患者,比较EDP1815、达格列净联合安立生坦与标准治疗的疗效。主要结局为基线至第14天死亡、有创机械通气、ECMO、心血管器官支持或肾衰竭的复合发生率。试验采用1:1:1随机分组,无固定样本量,计划进行基于生物标志物和临床终点的无效性分析。
要点
- TACTIC-E评估EDP1815及达格列净联合安立生坦对比标准治疗对COVID-19疾病进展的影响。
- 主要复合结局包括死亡、有创机械通气、ECMO、心血管器官支持或肾衰竭。
- 试验为开放标签适应性平台设计,无固定样本量,设无效性分析。
核心结论
- TACTIC-E旨在确定特定干预能否降低COVID-19相关疾病患者进展至器官衰竭或死亡的复合结局。
研究设计与样本
- 随机、平行臂、开放标签、适应性平台2/3期试验,纳入晚期1期/2期COVID-19相关疾病患者。
- 纳入年龄≥18岁、临床高度怀疑COVID-19相关疾病且风险计数>3或≥3(若风险计数包括影像学严重程度评分>3)的患者。
- 风险计数基于入院时影像学严重程度评分>3、男性、非白人 ethnicity、糖尿病、高血压、中性粒细胞>8.0 x10^9/L、年龄>40岁和CRP>40 mg/L各计1分。
- 患者在需要有创机械通气、心脏或肾脏支持之前入组,计划从英国多个中心招募。
- 随机化采用中央网络随机化服务,按中心分层,1:1:1分配至治疗臂或标准治疗。
关键数值与推荐
- 主要结局为基线至第14天死亡、有创机械通气、ECMO、心血管器官支持(正性肌力药或球囊泵)或肾衰竭(Cockcroft Gault估算肌酐清除率<15ml/min)的发生率。
- EDP1815剂量为2粒胶囊每日两次(1.6 x 10^11细胞),最多7天,若临床有效可延长至14天。
- 安立生坦5mg与达格列净10mg联合每日一次口服,最长14天。
- 无固定样本量;若生物标志物无效性分析不结论,约每臂125例后行基于临床终点的第二次无效性分析,随后每活跃臂229例和469例时进一步分析。
局限性
- 开放标签设计,数据分析不设盲。
- 无固定样本量,样本量依据无效性分析动态调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). TRIAL DESIGN: Randomised, parallel arm, open-label, adaptive platform Phase 2/3 trial of potential disease modifying therapies in patients with late stage 1/stage 2 COVID-19-related disease, with a diagnosis based either on a positive assay or high suspicion of COVID-19 infection by clinical, laboratory and radiological assessment. PARTICIPANTS: Patients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without a positive COVID-19 test) AND a risk count (as defined below) >3 OR ≥3 if risk count includes "Radiographic severity score >3". A risk count is calculated by the following features on admission (1 point for each): radiographic severity score >3, male gender, non-white ethnicity, diabetes, hypertension, neutrophils >8.0 x109/L, age >40 years and CRP >40 mg/L. Patients should be considered an appropriate subject for intervention with immunomodulatory or other disease modifying agents in the opinion of the investigator and are able to swallow capsules or tablets. The complete inclusion and exclusion criteria as detailed in the Additional file 1 should be fulfilled. Drug specific inclusion and exclusion criteria will also be applied to the active arms. Patients will be enrolled prior to the need for invasive mechanical ventilation, cardiac or renal support. Participants will be recruited across multiple centres in the UK including initially at Cambridge University Hospitals NHS Foundation Trust and St George's University NHS Foundation Trust. Other centres will be approached internationally in view of the evolving pandemic. INTERVENTION AND COMPARATOR: There is increasing evidence of the role of immunomodulation in altering the course of COVID-19. Additionally, various groups have demonstrated the presence of pulmonary shunting in patients with COVID-19 as well as other cardiovascular complications. TACTIC-E will assess the efficacy of the novel immunomodulatory agent EDP1815 versus the approved cardio-pulmonary drugs, Dapagliflozin in combination with Ambrisentan versus the prevailing standard of care. EDP1815 will be given as 2 capsules twice daily (1.6 x 1011 cells) for up to 7 days with the option to extend up to 14 days at the discretion of the principal investigator or their delegate, if the patient is felt to be clinically responding to treatment, is tolerating treatment, and is judged to be likely to benefit from a longer treatment course. Ambrisentan 5mg and Dapagliflozin 10mg will be given in combination once daily orally for up to maximum of 14 days. Patients will be randomised in a 1:1:1 ratio across treatments. Each active arm will be compared with standard of care alone. Additional arms may be added as the trial progresses. No comparisons will be made between active arms in this platform trial. MAIN OUTCOMES: The primary outcome is the incidence (from baseline up to Day 14) to the occurrence of the any one of the following events: death, invasive mechanical ventilation, extra corporeal membrane oxygenation, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). RANDOMISATION: Eligible patients will be randomised using a central web-based randomisation service (Sealed Envelope) in a 1:1:1 ratio, stratified by site to one of the treatment arms or standard of care. BLINDING (MASKING): This is an open-label trial. Data analysis will not be blinded. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): There is no fixed sample size for this study. There will be an early biomarker-based futility analysis performed at a point during the study. If this biomarker futility analysis is not conclusive, then a second futility analysis based on clinical endpoints will be performed after approximately 125 patients have been recruited per arm. Provisionally, further analyses of clinical endpoints will be performed after 229 patients per active arm and later 469 patients per arm have been recruited. Further additional analyses may be triggered by the independent data monitoring committee. TRIAL STATUS: TACTIC-E Protocol version number 1.0 date May 27th, 2020. Recruitment starts on the 3rd of July 2020. The end trial date will be 18 months after the last patient's last visit and cannot be accurately predicted at this time. TRIAL REGISTRATION: Registered on EU Clinical Trials Register EudraCT Number: 2020-002229-27 registered: 9 June 2020. The trial was also registered on ClinicalTrials.gov (NCT04393246) on 19 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Lu IN, Kulkarni S, Fisk M, et al. muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32736592. doi:10.1186/s13063-020-04618-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。